Frontlight ResearchEarly access
CompletedPhase 3
The Trial of SHR6508 in Secondary Hyperparathyroidism
Key facts
- Who runs it
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 498 people enrolled
- Started
- 14 Jun 2024
- Ended
- 11 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SHR6508 plus oral placebo tablets
- Cinacalcet plus intravenous placebo
- Record updated
- 12 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Able and willing to provide a written informed consent
- Diagnosed with end stage renal disease receiving maintenance hemodialysis
- Male or female
- Meet the Body Mass Index standard
- Stably use of concomitant medication of other therapies of SHPT
- Meet the standard of iPTH level, cCa
Who cannot take part
- Participated in clinical trials of other drugs
- Subjects with a history of malignant tumor
- Subjects with neuropsychiatric diseases
- Subjects with a history of cardiovascular diseases
- Subjects with gastrointestinal diseases
- Subjects with a history of surgery
- Subjects with a history of blood loss
- Subjects with a treatment history of similar drugs
- Allergic to a drug ingredient or component
- Subject with a history of alcohol abuse and drug abuse
- The investigators determined that other conditions were inappropriate for participation in this clinical trial
- Abnormal blood pressure, serum magnesium, serum transaminase, serum albumin
- Pregnant or nursing women
- No birth control during the specified period of time
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
The 2 groups in the trial
- Treatment groupTreatment being tested
Treatment: SHR6508 plus oral placebo tablets
- Active Control groupExisting treatment, for comparison
Treatment: Cinacalcet plus intravenous placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
- Record updated
- 12 December 2025